The Role of Oncogenic Viruses in the Pathogenesis of Hepatocellular Carcinoma

Clinics in Liver Disease

Volumn 15, Issue 2, 2011, Pages 261-279

  Zemel, Romy ^a   Issachar, Assaf ^a   Tur Kaspa, Ran ^a  

^a RABIN MEDICAL CENTER   (Israel)

Author keywords

Cirrhosis; Hepatitis b virus (HBV); Hepatitis c (HCV); Hepatocellular carcinoma (HCC)

Indexed keywords

8 ISOPROSTANE; AFLATOXIN B1; BUB1 RELATED PROTEIN; CORE PROTEIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; HEPATITIS B VACCINE; HEPATITIS B VIRUS X PROTEIN; HEPATITIS B(E) ANTIGEN; INTERFERON; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; LAMIVUDINE; MONTIRELIN; NONSTRUCTURAL PROTEIN 5A; NUCLEOSIDE ANALOG; ONCOLYTIC VIRUS; PEGINTERFERON; PROTEASOME; PROTEIN C FOS; PROTEIN P53; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; RIBAVIRIN; STRESS ACTIVATED PROTEIN KINASE; SUPEROXIDE DISMUTASE; UNINDEXED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

ALCOHOL CONSUMPTION; ANGIOGENESIS; ANTIBODY TITER; APOPTOSIS; ASIA; ASPERGILLUS; CANCER CELL; CANCER INVASION; CANCER SUSCEPTIBILITY; CELL ADHESION; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL DEATH; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL METABOLISM; CELL PROLIFERATION; CELL REGENERATION; CELL STRESS; CELL SURVIVAL; CELL TRANSFORMATION; CELL VIABILITY; CENTROSOME; CHROMOSOMAL INSTABILITY; CHROMOSOME TRANSLOCATION; CHRONIC HEPATITIS; CHRONIC INFLAMMATION; CIGARETTE SMOKING; CYTOPLASM; DELTA AGENT HEPATITIS; DIABETES MELLITUS; DISEASE SEVERITY; DNA DAMAGE; DNA VIRUS; DOWN REGULATION; DRUG EFFICACY; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; ENZYME INACTIVATION; EXPOSURE; GENE AMPLIFICATION; GENE DELETION; GENE DUPLICATION; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSFECTION; GENOMIC INSTABILITY; GROWTH INHIBITION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HOST; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNITY; INCIDENCE; INFLAMMATION; INFLAMMATORY CELL; ITALY; JAPAN; LIPID PEROXIDATION; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; MAINTENANCE THERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; METASTASIS; MICROARRAY ANALYSIS; MITOSIS; MIXED INFECTION; MONOTHERAPY; MUTATION; NECROSIS; NUCLEUS ACCUMBENS; OBESITY; OXIDATIVE STRESS; PERSISTENT INFECTION; PLOIDY; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN INTERACTION; PROTEOMICS; REVIEW; RISK FACTOR; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SPAIN; SPINDLE CELL; TRANSACTIVATION; TUMOR CELL; TUMOR GROWTH; UBIQUITINATION; UPREGULATION; VIRUS CARCINOGENESIS; VIRUS DNA CELL DNA INTERACTION; VIRUS GENOME; VIRUS HEPATITIS; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MALE;

EID: 79959304448     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2011.03.001     Document Type: Review

References (156)

1. Hanahan D., Bergers G., Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000, 105(8):1045-1047.
2. Schutte K., Bornschein J., Malfertheiner P. Hepatocellular carcinoma-epidemiological trends and risk factors. Dig Dis 2009, 27(2):80-92.
3. Franceschi S., Raza S.A. Epidemiology and prevention of hepatocellular carcinoma. Cancer Lett 2009, 286(1):5-8.
4. Marrero C.R., Marrero J.A. Viral hepatitis and hepatocellular carcinoma. Arch Med Res 2007, 38(6):612-620.
5. Wild C.P., Montesano R. A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention. Cancer Lett 2009, 286(1):22-28.
6. Nordenstedt H., White D.L., El-Serag H.B. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010, 42(Suppl 3):S206-S214.
7. Liu Z.M., Li L.Q., Peng M.H., et al. Hepatitis B virus infection contributes to oxidative stress in a population exposed to aflatoxin B1 and high-risk for hepatocellular carcinoma. Cancer Lett 2008, 263(2):212-222.
8. Sohn S., Jaitovitch-Groisman I., Benlimame N., et al. Retroviral expression of the hepatitis B virus x gene promotes liver cell susceptibility to carcinogen-induced site specific mutagenesis. Mutat Res 2000, 460(1):17-28.
9. Chan H.L., Tse C.H., Mo F., et al. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 2008, 26(2):177-182.
10. Yen-Hsuan N., Mei-Hwei C., Kuan-Jan W., et al. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology 2004, 127(6):1733-1738.
11. Cooksley W.G. Do we need to determine viral genotype in treating chronic hepatitis B?. J Viral Hepat 2010, 17(9):601-610.
12. Romeo R., Del Ninno E., Rumi M., et al. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 2009, 136:1629-1638.
13. Lim S.G., Mohammed R., Yuen M.F., et al. Prevention of hepatocellular carcinoma in hepatitis B virus infection. J Gastroenterol Hepatol 2009, 24(8):1352-1357.
14. Ueno Y., Sollano J.D., Farrell G.C. Prevention of hepatocellular carcinoma complicating chronic hepatitis C. J Gastroenterol Hepatol 2009, 24(4):531-536.
15. Raimondi S., Bruno S., Mondelli M.U., et al. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol 2009, 50(6):1142-1154.
16. Ishikawa T., Ichida T., Yamagiwa S., et al. High viral loads, serum alanine aminotransferase and gender are predictive factors for the development of hepatocellular carcinoma from viral compensated liver cirrhosis. J Gastroenterol Hepatol 2001, 16(11):1274-1281.
17. Gearhart T.L., Bouchard M.J. The hepatitis B virus X protein modulates hepatocyte proliferation pathways to stimulate viral replication. J Virol 2010, 84(6):2675-2686.
18. McLaughlin-Drubin M.E., Munger K. Viruses associated with human cancer. Biochim Biophys Acta 2008, 1782(3):127-150.
19. Bartosch B., Thimme R., Blum H.E., et al. Hepatitis C virus-induced hepatocarcinogenesis. J Hepatol 2009, 51(4):810-820.
20. Di Bisceglie A.M. Hepatitis B and hepatocellular carcinoma. Hepatology 2009, 49(Suppl 5):S56-S60.
21. Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 2004, 127(5 Suppl 1):S56-S61.
22. Farazi P.A., DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006, 6(9):674-687.
23. Berasain C., Castillo J., Perugorria M.J., et al. Inflammation and liver cancer: new molecular links. Ann N Y Acad Sci 2009, 1155:206-221.
24. Chemin I., Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett 2009, 286(1):52-59.
25. Hagen T.M., Huang S., Curnutte J., et al. Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. Proc Natl Acad Sci U S A 1994, 91(26):12808-12812.
26. Hsieh Y.H., Su I.J., Wang H.C., et al. Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. Carcinogenesis 2004, 25(10):2023-2032.
27. Fujita N., Sugimoto R., Ma N., et al. Comparison of hepatic oxidative DNA damage in patients with chronic hepatitis B and C. J Viral Hepat 2008, 15(7):498-507.
28. Tsai W.L., Chung R.T. Viral hepatocarcinogenesis. Oncogene 2010, 29(16):2309-2324.
29. Caldwell S., Park S.H. The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol 2009, 44(Suppl 19):96-101.
30. Madhoun M.F., Fazili J., Bright B.C., et al. Hepatitis C prevalence in patients with hepatocellular carcinoma without cirrhosis. Am J Med Sci 2010, 339(2):169-173.
31. Feitelson M.A., Lee J. Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett 2007, 252(2):157-170.
32. Cougot D., Neuveut C., Buendia M.A. HBV induced carcinogenesis. J Clin Virol 2005, 34(Suppl 1):S75-S78.
33. Brechot C., Kremsdorf D., Soussan P., et al. Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC): Molecular mechanisms and novel paradigms. Pathol Biol (Paris) 2010, 58(4):278-287.
34. Brechot C., Gozuacik D., Murakami Y., et al. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol 2000, 10(3):211-231.
35. Raimondo G., Burk R.D., Lieberman H.M., et al. Interrupted replication of hepatitis B virus in liver tissue of HBsAg carriers with hepatocellular carcinoma. Virology 1988, 166(1):103-112.
36. Butel J.S. Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease. Carcinogenesis 2000, 21(3):405-426.
37. Paterlini-Brechot P., Saigo K., Murakami Y., et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 2003, 22(25):3911-3916.
38. Carrillo-Infante C., Abbadessa G., Bagella L., et al. Viral infections as a cause of cancer (review). Int J Oncol 2007, 30(6):1521-1528.
39. Gale M., Foy E.M. Evasion of intracellular host defence by hepatitis C virus. Nature 2005, 436(7053):939-945.
40. Khu Y.L., Tan Y.J., Lim S.G., et al. Hepatitis C virus non-structural protein NS3 interacts with LMP7, a component of the immunoproteasome, and affects its proteasome activity. Biochem J 2004, 384(Pt 2):401-409.
41. Yun C., Cho H., Kim S.J., et al. Mitotic aberration coupled with centrosome amplification is induced by hepatitis B virus X oncoprotein via the Ras-mitogen-activated protein/extracellular signal-regulated kinase-mitogen-activated protein pathway. Mol Cancer Res 2004, 2(3):159-169.
42. Kim S., Park S.Y., Yong H., et al. HBV X protein targets hBubR1, which induces dysregulation of the mitotic checkpoint. Oncogene 2008, 27(24):3457-3464.
43. Molina-Jimenez F., Benedicto I., Murata M., et al. Expression of pituitary tumor-transforming gene 1 (PTTG1)/securin in hepatitis B virus (HBV)-associated liver diseases: evidence for an HBV X protein-mediated inhibition of PTTG1 ubiquitination and degradation. Hepatology 2010, 51(3):777-787.
44. Cao Z., Bai X., Guo X., et al. High prevalence of hepatitis B virus pre-S mutation and its association with hepatocellular carcinoma in Qidong, China. Arch Virol 2008, 153(10):1807-1812.
45. Smirnova I.S., Aksenov N.D., Kashuba E.V., et al. Hepatitis C virus core protein transforms murine fibroblasts by promoting genomic instability. Cell Oncol 2006, 28(4):177-190.
46. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
47. Gao Z.Y., Li T., Wang J., et al. Mutations in preS genes of genotype C hepatitis B virus in patients with chronic hepatitis B and hepatocellular carcinoma. J Gastroenterol 2007, 42(9):761-768.
48. Lin C.L., Liu C.H., Chen W., et al. Association of pre-S deletion mutant of hepatitis B virus with risk of hepatocellular carcinoma. J Gastroenterol Hepatol 2007, 22(7):1098-1103.
49. Kasprzak A., Adamek A. Role of hepatitis C virus proteins (C, NS3, NS5A) in hepatic oncogenesis. Hepatol Res 2008, 38(1):1-26.
50. Tsutsumi T., Suzuki T., Moriya K., et al. Hepatitis C virus core protein activates ERK and p38 MAPK in cooperation with ethanol in transgenic mice. Hepatology 2003, 38(4):820-828.
51. Zemel R., Gerechet S., Greif H., et al. Cell transformation induced by hepatitis C virus NS3 serine protease. J Viral Hepat 2001, 8(2):96-102.
52. Mankouri J., Griffin S., Harris M. The hepatitis C virus non-structural protein NS5A alters the trafficking profile of the epidermal growth factor receptor. Traffic 2008, 9(9):1497-1509.
53. Miyaki M., Sato C., Sakai K., et al. Malignant transformation and EGFR activation of immortalized mouse liver epithelial cells caused by HBV enhancer-X from a human hepatocellular carcinoma. Int J Cancer 2000, 85(4):518-522.
54. Bouchard M., Giannakopoulos S., Wang E.H., et al. Hepatitis B virus HBx protein activation of cyclin A-cyclin-dependent kinase 2 complexes and G1 transit via a Src kinase pathway. J Virol 2001, 75(9):4247-4257.
55. Klein N.P., Schneider R.J. Activation of Src family kinases by hepatitis B virus HBx protein and coupled signaling to Ras. Mol Cell Biol 1997, 17(11):6427-6436.
56. Yang S.Z., Zhang L.D., Zhang Y., et al. HBx protein induces EMT through c-Src activation in SMMC-7721 hepatoma cell line. Biochem Biophys Res Commun 2009, 382(3):555-560.
57. Shih W.L., Kuo M.L., Chuang S.E., et al. Hepatitis B virus X protein activates a survival signaling by linking SRC to phosphatidylinositol 3-kinase. J Biol Chem 2003, 278(34):31807-31813.
58. Benn J., Schneider R.J. Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc Natl Acad Sci U S A 1994, 91(22):10350-10354.
59. Wang H.D., Trivedi A., Johnson D.L. Regulation of RNA polymerase I-dependent promoters by the hepatitis B virus X protein via activated Ras and TATA-binding protein. Mol Cell Biol 1998, 18(12):7086-7094.
60. Shan C., Xu F., Zhang S., et al. Hepatitis B virus X protein promotes liver cell proliferation via a positive cascade loop involving arachidonic acid metabolism and p-ERK1/2. Cell Res 2010, 20(5):563-575.
61. Twu J.S., Lai M.Y., Chen D.S., et al. Activation of protooncogene c-jun by the X protein of hepatitis B virus. Virology 1993, 192(1):346-350.
62. Benn J., Su F., Doria M., et al. Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-Jun N-terminal mitogen-activated protein kinases. J Virol 1996, 70(8):4978-4985.
63. Bock C.T., Toan N.L., Koeberlein B., et al. Subcellular mislocalization of mutant hepatitis B X proteins contributes to modulation of STAT/SOCS signaling in hepatocellular carcinoma. Intervirology 2008, 51(6):432-443.
64. Brenndorfer E.D., Karthe J., Frelin L., et al. Nonstructural 3/4A protease of hepatitis C virus activates epithelial growth factor-induced signal transduction by cleavage of the T-cell protein tyrosine phosphatase. Hepatology 2009, 49(6):1810-1820.
65. Tsuchihara K., Hijikata M., Fukuda K., et al. Hepatitis C virus core protein regulates cell growth and signal transduction pathway transmitting growth stimuli. Virology 1999, 258(1):100-107.
66. Giambartolomei S., Covone F., Levrero M., et al. Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein. Oncogene 2001, 20(20):2606-2610.
67. Erhardt A., Hassan M., Heintges T., et al. Hepatitis C virus core protein induces cell proliferation and activates ERK, JNK, and p38 MAP kinases together with the MAP kinase phosphatase MKP-1 in a HepG2 Tet-Off cell line. Virology 2002, 292(2):272-284.
68. Qadri I., Iwahashi M., Capasso J.M., et al. Induced oxidative stress and activated expression of manganese superoxide dismutase during hepatitis C virus replication: role of JNK, p38 MAPK and AP-1. Biochem J 2004, 378(Pt 3):919-928.
69. Hassan M., Ghozlan H., Abdel-Kader O. Activation of c-Jun NH2-terminal kinase (JNK) signaling pathway is essential for the stimulation of hepatitis C virus (HCV) non-structural protein 3 (NS3)-mediated cell growth. Virology 2005, 333(2):324-336.
70. Macdonald A., Chan J.K., Harris M. Perturbation of epidermal growth factor receptor complex formation and Ras signalling in cells harbouring the hepatitis C virus subgenomic replicon. J Gen Virol 2005, 86(Pt 4):1027-1033.
71. Tan S.L., Nakao H., He Y., et al. NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. Proc Natl Acad Sci U S A 1999, 96(10):5533-5538.
72. Georgopoulou U., Caravokiri K., Mavromara P. Suppression of the ERK1/2 signaling pathway from HCV NS5A protein expressed by herpes simplex recombinant viruses. Arch Virol 2003, 148(2):237-251.
73. Qiao L., Leach K., McKinstry R., et al. Hepatitis B virus X protein increases expression of p21(Cip-1/WAF1/MDA6) and p27(Kip-1) in primary mouse hepatocytes, leading to reduced cell cycle progression. Hepatology 2001, 34(5):906-917.
74. Choi B.H., Choi M., Jeon H.Y., et al. Hepatitis B viral X protein overcomes inhibition of E2F1 activity by pRb on the human Rb gene promoter. DNA Cell Biol 2001, 20(2):75-80.
75. Hsieh Y.H., Su I.J., Wang H.C., et al. Hepatitis B virus pre-S2 mutant surface antigen induces degradation of cyclin-dependent kinase inhibitor p27Kip1 through c-Jun activation domain-binding protein 1. Mol Cancer Res 2007, 5(10):1063-1072.
76. Kalra N., Kumar V. The X protein of hepatitis B virus binds to the F box protein Skp2 and inhibits the ubiquitination and proteasomal degradation of c-Myc. FEBS Lett 2006, 580(2):431-436.
77. Tu H., Bonura C., Giannini C., et al. Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res 2001, 61(21):7803-7810.
78. Aileen M., Simon R., Susan E.D., et al. Relation between hepatocyte G1 arrest, impaired hepatic regeneration, and fibrosis in chronic hepatitis C virus infection. Gastroenterology 2005, 128(1):33-42.
79. Munakata T., Nakamura M., Liang Y., et al. Down-regulation of the retinoblastoma tumor suppressor by the hepatitis C virus NS5B RNA-dependent RNA polymerase. Proc Natl Acad Sci U S A 2005, 102(50):18159-18164.
80. Munakata T., Liang Y., Kim S., et al. Hepatitis C virus induces E6AP-dependent degradation of the retinoblastoma protein. PLoS Pathog 2007, 3(9):1335-1347.
81. Hassan M., Ghozlan H., Abdel-Kader O. Activation of RB/E2F signaling pathway is required for the modulation of hepatitis C virus core protein-induced cell growth in liver and non-liver cells. Cell Signal 2004, 16(12):1375-1385.
82. Ray R.B., Steele R., Meyer K., et al. Hepatitis C virus core protein represses p21WAF1/Cip1/Sid1 promoter activity. Gene 1998, 208(2):331-336.
83. Jung E.Y., Lee M.N., Yang H.Y., et al. The repressive activity of hepatitis C virus core protein on the transcription of p21(waf1) is regulated by protein kinase A-mediated phosphorylation. Virus Res 2001, 79(1-2):109-115.
84. Yoshida I., Oka K., Hidajat R., et al. Inhibition of p21/Waf1/Cip1/Sdi1 expression by hepatitis C virus core protein. Microbiol Immunol 2001, 45(10):689-697.
85. Ghosh A.K., Steele R., Meyer K., et al. Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth. J Gen Virol 1999, 80(Pt 5):1179-1183.
86. Honda M., Kaneko S., Shimazaki T., et al. Hepatitis C virus core protein induces apoptosis and impairs cell-cycle regulation in stably transformed Chinese hamster ovary cells. Hepatology 2000, 31(6):1351-1359.
87. Cho J.W., Baek W.K., Suh S.I., et al. Hepatitis C virus core protein promotes cell proliferation through the upregulation of cyclin E expression levels. Liver 2001, 21(2):137-142.
88. Street A., Macdonald A., McCormick C., et al. Hepatitis C virus NS5A-mediated activation of phosphoinositide 3-kinase results in stabilization of cellular beta-catenin and stimulation of beta-catenin-responsive transcription. J Virol 2005, 79(8):5006-5016.
89. Milward A., Mankouri J., Harris M. Hepatitis C virus NS5A protein interacts with {beta}-catenin and stimulates its transcriptional activity in a phosphoinositide-3 kinase-dependent fashion. J Gen Virol 2010, 91(2):373-381.
90. Ding Q., Xia W., Liu J.C., et al. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell 2005, 19(2):159-170.
91. Longato L., de la Monte S., Kuzushita N., et al. Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver. Hepatology 2009, 49(6):1935-1943.
92. Shih W.L., Kuo M.L., Chuang S.E., et al. Hepatitis B virus X protein inhibits transforming growth factor-beta -induced apoptosis through the activation of phosphatidylinositol 3-kinase pathway. J Biol Chem 2000, 275(33):25858-25864.
93. Lee Y.I., Kang-Park S., Do S.I. The hepatitis B virus-X protein activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. J Biol Chem 2001, 276(20):16969-16977.
94. Ueda H., Ullrich S.J., Gangemi J.D., et al. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet 1995, 9(1):41-47.
95. Wang X.W., Gibson M.K., Vermeulen W., et al. Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res 1995, 55(24):6012-6016.
96. Clippinger A.J., Bouchard M.J. Hepatitis B virus HBx protein localizes to mitochondria in primary rat hepatocytes and modulates mitochondrial membrane potential. J Virol 2008, 82(14):6798-6811.
97. Su F., Theodosis C.N., Schneider R.J. Role of NF-kappaB and myc proteins in apoptosis induced by hepatitis B virus HBx protein. J Virol 2001, 75(1):215-225.
98. Yun C., Um H.R., Jin Y.H., et al. NF-kappaB activation by hepatitis B virus X (HBx) protein shifts the cellular fate toward survival. Cancer Lett 2002, 184(1):97-104.
99. Tanimoto H., Yan Y., Clarke J., et al. Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res 1997, 57(14):2884-2887.
100. Magee J.A., Araki T., Patil S., et al. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 2001, 61(15):5692-5696.
101. Zhang J.L., Zhao W.G., Wu K.L., et al. Human hepatitis B virus X protein promotes cell proliferation and inhibits cell apoptosis through interacting with a serine protease Hepsin. Arch Virol 2005, 150(4):721-741.
102. Zhang X., Dong N., Yin L., et al. Hepatitis B virus X protein upregulates survivin expression in hepatoma tissues. J Med Virol 2005, 77(3):374-381.
103. Beresford P.J., Zhang D., Oh D.Y., et al. Granzyme A activates an endoplasmic reticulum-associated caspase-independent nuclease to induce single-stranded DNA nicks. J Biol Chem 2001, 276(46):43285-43293.
104. Lamontagne J., Pinkerton M., Block T.M., et al. Hepatitis B and hepatitis C virus replication upregulates serine protease inhibitor Kazal, resulting in cellular resistance to serine protease-dependent apoptosis. J Virol 2010, 84(2):907-917.
105. Kamegaya Y., Hiasa Y., Zukerberg L., et al. Hepatitis C virus acts as a tumor accelerator by blocking apoptosis in a mouse model of hepatocarcinogenesis. Hepatology 2005, 41(3):660-667.
106. Machida K., Tsukiyama-Kohara K., Seike E., et al. Inhibition of cytochrome c release in Fas-mediated signaling pathway in transgenic mice induced to express hepatitis C viral proteins. J Biol Chem 2001, 276(15):12140-12146.
107. Majumder M., Ghosh A.K., Steele R., et al. Hepatitis C virus NS5A protein impairs TNF-mediated hepatic apoptosis, but not by an anti-FAS antibody, in transgenic mice. Virology 2002, 294(1):94-105.
108. Ghosh A.K., Majumder M., Steele R., et al. Hepatitis C virus NS5A protein protects against TNF-alpha mediated apoptotic cell death. Virus Res 2000, 67(2):173-178.
109. Lan K.H., Sheu M.L., Hwang S.J., et al. HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis. Oncogene 2002, 21(31):4801-4811.
110. Nanda S.K., Herion D., Liang T.J. The SH3 binding motif of HCV [corrected] NS5A protein interacts with Bin1 and is important for apoptosis and infectivity. Gastroenterology 2006, 130(3):794-809.
111. He Y., Nakao H., Tan S.L., et al. Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase. J Virol 2002, 76(18):9207-9217.
112. Peng L., Liang D., Tong W., et al. Hepatitis C Virus NS5A activates the mammalian target of rapamycin (mTOR) pathway, contributing to cell survival by disrupting the interaction between FK506-binding protein 38 (FKBP38) and mTOR. J Biol Chem 2010, 285(27):20870-20881.
113. Wang J., Tong W., Zhang X., et al. Hepatitis C virus non-structural protein NS5A interacts with FKBP38 and inhibits apoptosis in Huh7 hepatoma cells. FEBS Lett 2006, 580(18):4392-4400.
114. Saito K., Meyer K., Warner R., et al. Hepatitis C virus core protein inhibits tumor necrosis factor alpha-mediated apoptosis by a protective effect involving cellular FLICE inhibitory protein. J Virol 2006, 80(9):4372-4379.
115. Hara Y., Hino K., Okuda M., et al. Hepatitis C virus core protein inhibits deoxycholic acid-mediated apoptosis despite generating mitochondrial reactive oxygen species. J Gastroenterol 2006, 41(3):257-268.
116. Ray R.B., Steele R., Meyer K., et al. Transcriptional repression of p53 promoter by hepatitis C virus core protein. J Biol Chem 1997, 272(17):10983-10986.
117. Herzer K., Weyer S., Krammer P.H., et al. Hepatitis C virus core protein inhibits tumor suppressor protein promyelocytic leukemia function in human hepatoma cells. Cancer Res 2005, 65(23):10830-10837.
118. Lee S.H., Kim Y.K., Kim C.S., et al. E2 of hepatitis C virus inhibits apoptosis. J Immunol 2005, 175(12):8226-8235.
119. Tahara H., Nakanishi T., Kitamoto M., et al. Telomerase activity in human liver tissues: comparison between chronic liver disease and hepatocellular carcinomas. Cancer Res 1995, 55(13):2734-2736.
120. Miura N., Horikawa I., Nishimoto A., et al. Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis. Cancer Genet Cytogenet 1997, 93(1):56-62.
121. Yokota T., Suda T., Igarashi M., et al. Telomere length variation and maintenance in hepatocarcinogenesis. Cancer 2003, 98(1):110-118.
122. Zhang X., Dong N., Zhang H., et al. Effects of hepatitis B virus X protein on human telomerase reverse transcriptase expression and activity in hepatoma cells. J Lab Clin Med 2005, 145(2):98-104.
123. Liu H., Luan F., Ju Y., et al. In vitro transfection of the hepatitis B virus PreS2 gene into the human hepatocarcinoma cell line HepG2 induces upregulation of human telomerase reverse transcriptase. Biochem Biophys Res Commun 2007, 355(2):379-384.
124. Zhu Z., Wilson A.T., Gopalakrishna K., et al. Hepatitis C virus core protein enhances Telomerase activity in Huh7 cells. J Med Virol 2010, 82(2):239-248.
125. Ray R.B., Meyer K., Ray R. Hepatitis C virus core protein promotes immortalization of primary human hepatocytes. Virology 2000, 271(1):197-204.
126. Majano P.L., Garcia-Monzon C., Lopez-Cabrera M., et al. Inducible nitric oxide synthase expression in chronic viral hepatitis. Evidence for a virus-induced gene upregulation. J Clin Invest 1998, 101(7):1343-1352.
127. Moon E.J., Jeong C.H., Jeong J.W., et al. Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1alpha. FASEB J 2004, 18(2):382-384.
128. Sanz-Cameno P., Martin-Vilchez S., Lara-Pezzi E., et al. Hepatitis B virus promotes angiopoietin-2 expression in liver tissue: role of HBV x protein. Am J Pathol 2006, 169(4):1215-1222.
129. Lee S.W., Lee Y.M., Bae S.K., et al. Human hepatitis B virus X protein is a possible mediator of hypoxia-induced angiogenesis in hepatocarcinogenesis. Biochem Biophys Res Commun 2000, 268(2):456-461.
130. Yang J.C., Teng C.F., Wu H.C., et al. Enhanced expression of vascular endothelial growth factor-A in ground glass hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis. Hepatology 2009, 49(6):1962-1971.
131. Zhang J., Niu D., Sui J., et al. Protein profile in hepatitis B virus replicating rat primary hepatocytes and HepG2 cells by iTRAQ-coupled 2-D LC-MS/MS analysis: insights on liver angiogenesis. Proteomics 2009, 9(10):2836-2845.
132. Hassan M., Selimovic D., Ghozlan H., et al. Hepatitis C virus core protein triggers hepatic angiogenesis by a mechanism including multiple pathways. Hepatology 2009, 49(5):1469-1482.
133. Nasimuzzaman M., Waris G., Mikolon D., et al. Hepatitis C virus stabilizes hypoxia-inducible factor 1alpha and stimulates the synthesis of vascular endothelial growth factor. J Virol 2007, 81(19):10249-10257.
134. Kanda T., Steele R., Ray R., et al. Hepatitis C virus core protein augments androgen receptor-mediated signaling. J Virol 2008, 82(22):11066-11072.
135. Chung T.W., Lee Y.C., Kim C.H. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. FASEB J 2004, 18(10):1123-1125.
136. Lara-Pezzi E., Gomez-Gaviro M.V., Galvez B.G., et al. The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression. J Clin Invest 2002, 110(12):1831-1838.
137. Liu L.P., Liang H.F., Chen X.P., et al. The role of NF-kappaB in Hepatitis b virus X protein-mediated upregulation of VEGF and MMPs. Cancer Invest 2010, 28(5):443-451.
138. Yu F.L., Liu H.J., Lee J.W., et al. Hepatitis B virus X protein promotes cell migration by inducing matrix metalloproteinase-3. J Hepatol 2005, 42(4):520-527.
139. Matsuzaki K., Murata M., Yoshida K., et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 2007, 46(1):48-57.
140. Battaglia S., Benzoubir N., Nobilet S., et al. Liver cancer-derived hepatitis C virus core proteins shift TGF-beta responses from tumor suppression to epithelial-mesenchymal transition. PLoS One 2009, 4(2):e4355.
141. Wright T.L. Antiviral therapy and primary and secondary prevention of hepatocellular carcinoma. Hepatol Res 2007, 37(Suppl 2):S294-S298.
142. Lanier A.P., Holck P., Ehrsam Day G., et al. Childhood cancer among Alaska Natives. Pediatrics 2003, 112(5):e396.
143. Wichajarn K., Kosalaraksa P., Wiangnon S. Incidence of hepatocellular carcinoma in children in Khon Kaen before and after national hepatitis B vaccine program. Asian Pac J Cancer Prev 2008, 9(3):507-509.
144. Lin S.M., Yu M.L., Lee C.M., et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007, 46(1):45-52.
145. Camma C., Giunta M., Andreone P., et al. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001, 34(4):593-602.
146. Yang Y.F., Zhao W., Zhong Y.D., et al. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat 2009, 16(4):265-271.
147. Ohata K., Hamasaki K., Toriyama K., et al. High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol 2004, 19(6):670-675.
148. Ikeda K., Arase Y., Kobayashi M., et al. Consistently low hepatitis B virus DNA saves patients from hepatocellular carcinogenesis in HBV-related cirrhosis. A nested case-control study using 96 untreated patients. Intervirology 2003, 46(2):96-104.
149. Sung J.J., Tsoi K.K., Wong V.W., et al. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008, 28(9):1067-1077.
150. Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351(15):1521-1531.
151. Yuen M.F., Seto W.K., Chow D.H., et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007, 12(8):1295-1303.
152. Yoshida H., Shiratori Y., Moriyama M., et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999, 131(3):174-181.
153. Azzaroli F., Accogli E., Nigro G., et al. Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis. World J Gastroenterol 2004, 10(21):3099-3102.
154. Lee W.M., Dienstag J.L., Lindsay K.L., et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004, 25(5):472-492.
155. Afdhal N.H., Brown R., Freilich B., et al. Colchicine versus PEG interferon alfa-2b long-term therapy: results of the 4-year copilot trial. J Hepatol 2008, 48(Suppl 2):S4.
156. 3 cirrhosis maintenance trial (Co-Pilot abstract). J Hepatol 2009, 50(Suppl 1):S22.